An observational study in Latent Tuberculosis Infection and Tuberculosis, sponsored by Centers for Disease Control and Prevention. Completed at 10 sites in United States. Per ClinicalTrials.gov, last updated 2021-01-28.
Sponsored by Centers for Disease Control and Prevention · Observational
This is a prospective cohort study of persons tested for latent tuberculosis infection at either high risk for exposure to Mycobacterium tuberculosis or high risk for progression to tuberculosis disease. The study will assess the relative performance and cost of three diagnostic tests for latent tuberculosis infection (tuberculin skin test, QuantiFERON-TB Gold In-Tube, and T-SPOT.TB) and will examine the rates of positive results among the cohort. This study will also determine the risk and rate of progression to active TB disease, overall and by the results of the three tests.
6,687 studies on the registry are indexed under Infections; 807 are open to participants now.
This study's enrollment of 21,334 is above the median of 240 across 2,136 observational studies indexed under Infections.
Browse Infections studies →Centers for Disease Control and Prevention is the lead sponsor of 273 studies on the registry; 2 are open to participants now.
Of its 11 completed or terminated interventional studies of FDA-regulated products, 8 (73%) have results posted.
Counted across the registry records on this site, refreshed daily.
Individuals at high risk for latent tuberculosis infection or at high risk for progression to tuberculosis from health clinics, hospitals, or health departments at the 10 Tuberculosis Epidemiologic Studies Consortium sites within the United States: California Department of Public Health, Denver Health and Hospital Authority, Duke University, Emory University, Hawaii Department of Health, Maricopa County Department of Public Health, Maryland Department of Public Health, Public Health Seattle-King County, University of Florida Board of Trustees, and University of North Texas Health Science Center
Study participants must be at high risk for latent tuberculosis infection or at high risk for progression to tuberculosis disease, including being a:
Participants may be enrolled before the culture results for the index/source case are available. If the criteria described above are not met once results are available, the participant will be terminated from the study and any collected data will be immediately destroyed.
A close contact is defined as spending 15 or more hours over a week's period in a shared airspace with a person with active pulmonary tuberculosis while that person was presumed to be infectious.
4.2 Subject Exclusion Criteria
Subjects meeting any of the exclusion criteria will be excluded from study enrollment.
Latent tuberculosis infection
Time frame: 3 days
Tuberculosis disease at 6 months
Time frame: 6 months
Tuberculosis disease at 12 months
Time frame: 12 months
Tuberculosis disease at 18 months
Time frame: 18 months
Tuberculosis disease at 24 months
Time frame: 24 months
This study is completed, as verified in Jan 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Centers for Disease Control and Prevention